Privium Fund Management B.V. Boosts Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Key Points

• Privium Fund Management B.V. increased its holdings in Intellia Therapeutics by 111.9%, owning over 58,000 shares after purchasing an additional 31,000 shares.
• Institutional investors now collectively own 88.77% of Intellia Therapeutics, with notable increases in stakes from firms like Cambridge Investment Research and D.A. Davidson & CO.
• Intellia's recent earnings report showed a loss of ($1.10) EPS, which was better than the expected loss, alongside a revenue of $16.63 million, surpassing consensus estimates.

Privium Fund Management B.V. boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 111.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,709 shares of the company's stock after acquiring an additional 31,000 shares during the quarter. Privium Fund Management B.V. owned about 0.06% of Intellia Therapeutics worth $417,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTLA. Ensign Peak Advisors Inc boosted its position in shares of Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after buying an additional 1,100 shares during the period. Virtus ETF Advisers LLC boosted its holdings in Intellia Therapeutics by 47.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock valued at $61,000 after purchasing an additional 1,692 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Intellia Therapeutics by 28.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,148 shares of the company's stock valued at $95,000 after purchasing an additional 1,808 shares during the period. GF Fund Management CO. LTD. purchased a new position in Intellia Therapeutics in the fourth quarter valued at $25,000. Finally, Harbour Investments Inc. boosted its holdings in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after purchasing an additional 2,264 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Down 4.5%

NTLA stock traded down $0.54 during trading on Tuesday, hitting $11.58. The company had a trading volume of 3,450,548 shares, compared to its average volume of 4,046,963. The firm has a market cap of $1.20 billion, a PE ratio of -2.21 and a beta of 2.31. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $24.16. The firm has a 50-day moving average price of $10.25 and a 200-day moving average price of $9.44.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company's revenue for the quarter was down 42.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.12) EPS. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 12,534 shares of company stock valued at $153,837 in the last quarter. 3.10% of the stock is owned by insiders.

Analysts Set New Price Targets

NTLA has been the subject of a number of recent research reports. Guggenheim decreased their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price for the company in a report on Monday, April 21st. Chardan Capital reiterated a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Canaccord Genuity Group decreased their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a report on Tuesday, June 3rd. Finally, Wedbush reiterated a "neutral" rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 16th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $33.37.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.